Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Biological Products, (No Diagnostic Substances)

Standard Industrial Classification: SIC 2836

Industry Insider Sentiment Analysis

The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-10-05 20:05 2026-10-01 TWST Twist Bioscience Corp Leproust Emily M. Director, Officer SELL $189.04 46,391 $8,769,796 567,308
2026-10-05 20:05 2026-10-02 TWST Twist Bioscience Corp WERNER ROBERT F. Officer SELL $188.88 1,482 $279,926 42,917
2026-10-05 20:05 2026-10-02 TWST Twist Bioscience Corp Laponis Adam Officer SELL $188.88 8,057 $1,521,838 100,576
2026-10-05 20:05 2026-10-02 TWST Twist Bioscience Corp Green Paula Officer SELL $188.88 10,088 $1,905,462 106,632
2026-10-05 20:05 2026-10-02 TWST Twist Bioscience Corp Finn Patrick John Officer SELL $188.88 25,714 $4,856,963 185,088
2026-10-05 20:05 2026-10-02 TWST Twist Bioscience Corp Cho Dennis Officer SELL $188.88 9,514 $1,797,042 63,789
2026-10-05 20:03 2026-10-01 XFOR X4 Pharmaceuticals, Inc KIRSKE DAVID Officer SELL $2.86 11,767 $33,658 155,983
2026-10-06 00:12 2026-10-01 ADPT Adaptive Biotechnologies Corp LO FRANCIS Officer OPT+S $28.28 26,792 $757,697 220,867
2026-10-06 00:15 2026-10-01 ADPT Adaptive Biotechnologies Corp RUBINSTEIN JULIE Officer OPT+S $28.46 35,643 $1,014,328 377,802
2026-10-06 00:18 2026-10-01 GRML Greenland Mines Ltd El-Dada Riad Hussein SELL $9.35 3,500 $32,727 0
2026-10-05 23:42 2026-10-02 IMVT Immunovant, Inc. Venker Eric Director, Officer OPT+S $34.11 3,506 $119,590 257,075
2026-10-05 21:20 2026-10-01 PALI PALISADE BIO, INC. Williams Donald Allen Director BUY $1.44 20,000 $28,800 1,590,294
2026-10-02 20:09 2026-10-01 MAZE Maze Therapeutics, Inc. Bernstein Harold Officer OPT+S $26.93 16,141 $434,743 0
2026-10-02 20:27 2026-10-01 BNTX BioNTech SE Sahin Ugur Officer, 10% owner SELL $97.09 34,000 $3,301,067 180,209
2026-10-02 20:05 2026-10-01 BEAM Beam Therapeutics Inc. Cavanagh Bethany J Officer SELL $24.41 187 $4,565 50,984
2026-10-02 21:00 2026-09-30 TECX Tectonic Therapeutic, Inc. McNamara Peter Officer SELL $23.04 536 $12,349 54,305
2026-10-02 20:12 2026-10-01 MAZE Maze Therapeutics, Inc. Coloma Jason V Director, Officer SELL $27.02 34,501 $932,258 191,447
2026-10-02 20:05 2026-10-01 PCVX Vaxcyte, Inc. Wassil Jim Officer OPT+S $56.67 2,250 $127,513 145,435
2026-10-02 20:40 2026-10-01 GILD GILEAD SCIENCES, INC. O'Day Daniel Patrick Director, Officer SELL $147.90 15,000 $2,218,508 566,683
2026-10-02 20:05 2026-10-01 ACOG Alpha Cognition Inc. Opaleye Management Inc. 10% owner BUY $8.69 19,050 $165,634 3,222,954
2026-10-02 20:38 2026-10-01 HALO HALOZYME THERAPEUTICS, INC. Posard Matthew L. Director SELL $108.54 5,230 $567,661 53,609
2026-10-02 12:00 2026-10-01 CMPX Compass Therapeutics, Inc. Lerner Neil Officer BUY $0.92 20,000 $18,400 420,000
2026-10-01 22:00 2026-09-29 RVMD Revolution Medicines, Inc. Sandler Alan B. Officer OPT+S $202.14 6,309 $1,275,294 52,559
2026-10-01 21:20 2026-10-01 KYMR Kymera Therapeutics, Inc. Mainolfi Nello Director, Officer OPT+S $113.80 30,000 $3,413,916 666,568
2026-10-01 20:30 2026-09-29 SLBT SL Science Holding Ltd Wang Ching-Dong Director, Officer, 10% owner BUY $2,272,653.00 4,545,306 $10,329,903,316,818 333,832,129
2026-10-01 20:06 2026-09-29 MAZE Maze Therapeutics, Inc. Dandekar Atul Officer OPT+S $27.06 7,500 $202,921 32,316
2026-09-30 22:51 2026-09-29 BCDA BioCardia, Inc. Altman Peter Director, Officer BUY $1.03 1,000 $1,030 384,885
2026-09-30 20:29 2026-09-28 KOD Kodiak Sciences Inc. BAKER BROS. ADVISORS LP Director, 10% owner BUY $72.57 807,840 $58,625,676 19,121,134
2026-09-30 20:29 2026-09-29 BNTX BioNTech SE Sahin Ugur Officer, 10% owner SELL $98.19 66,000 $6,480,659 214,209
2026-09-30 20:30 2026-09-28 KOD Kodiak Sciences Inc. BAKER BROS. ADVISORS LP Director, 10% owner BUY $83.58 418,323 $34,963,060 19,515,907
2026-09-30 20:31 2026-09-28 KOD Kodiak Sciences Inc. BAKER BROS. ADVISORS LP Director, 10% owner BUY $88.59 715,592 $63,397,587 20,191,214
2026-09-30 20:15 2026-09-28 DTIL PRECISION BIOSCIENCES INC Frankel Stanley Director BUY $6.00 1,000 $6,000 41,478
2026-09-29 22:00 2026-09-25 RVMD Revolution Medicines, Inc. Cislini Jeff Officer SELL $207.32 765 $158,600 51,776
2026-09-29 11:00 2026-09-25 DTIL PRECISION BIOSCIENCES INC Germano Geno J Director BUY $6.28 2,609 $16,385 47,492
2026-09-29 11:00 2026-09-25 DTIL PRECISION BIOSCIENCES INC Brown Melinda Director BUY $6.27 1,135 $7,116 45,481
2026-09-28 23:57 2026-09-24 ACOG Alpha Cognition Inc. Opaleye Management Inc. 10% owner BUY $8.53 31,763 $270,802 3,203,904
2026-09-28 22:00 2026-09-24 RVMD Revolution Medicines, Inc. Mancini Anthony Officer OPT+S $200.45 3,708 $743,285 39,765
2026-09-28 21:47 2026-09-25 INBX Inhibrx Biosciences, Inc. Lappe Mark Director, Officer BUY $99.88 10,000 $998,784 740,548
2026-09-28 21:16 2026-09-25 BNTX BioNTech SE Sahin Ugur Officer, 10% owner SELL $98.57 61,000 $6,012,502 280,209
2026-09-25 20:09 2026-09-24 RGEN REPLIGEN CORP Loeillot Olivier Director, Officer OPT+S $190.00 12,946 $2,459,740 48,369
2026-09-25 20:05 2026-09-23 IMVT Immunovant, Inc. Van Tuyl Christopher Officer SELL $36.36 2,846 $103,481 176,545
2026-09-25 20:05 2026-09-24 TWST Twist Bioscience Corp Leproust Emily M. Director, Officer SELL $177.38 5,203 $922,907 613,699
2026-09-25 12:01 2026-09-24 CMPX Compass Therapeutics, Inc. Lerner Neil Officer BUY $1.14 2,500 $2,850 400,000
2026-09-24 20:26 2026-09-23 BNTX BioNTech SE Sahin Ugur Officer, 10% owner SELL $99.17 69,000 $6,842,744 341,209
2026-09-24 22:00 2026-09-22 RVMD Revolution Medicines, Inc. ANDERSON ELIZABETH M Director OPT+S $193.04 10,143 $1,958,016 4,333
2026-09-24 21:35 2026-09-22 CRSP CRISPR Therapeutics AG KASINGER JAMES R. Officer OPT+S $60.24 10,400 $626,460 94,784
2026-09-24 20:40 2026-09-22 ENGN enGene Therapeutics Inc. Grossman William Director, Officer BUY $1.97 5,102 $10,051 5,102
2026-09-24 00:14 2026-09-23 BCDA BioCardia, Inc. Altman Peter Director, Officer BUY $1.05 1,900 $1,995 383,885
2026-09-23 21:35 2026-09-21 ETRA Electra Therapeutics, Inc. GORDON CARL L Director, 10% owner BUY $15.00 1,333,333 $19,999,995 1,758,279
2026-09-23 21:29 2026-09-21 ETRA Electra Therapeutics, Inc. ORBIMED ADVISORS LLC Director, 10% owner BUY $15.00 1,333,333 $19,999,995 1,758,279
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Biological Products, (No Diagnostic Substances)

Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.